The words approved in red letters.
Advertisement
09/20/2021

Cipla obtains FDA nod for generic Durezol

Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA.
Sandra Levy
Senior Editor
Sandra Levy profile picture

The Food and Drug Administration has approved Cipla’s difluprednate ophthalmic emulsion 0.05%.

The medication is the generic of Novartis’ Durezol.

It is used for the treatment of inflammation and pain associated with ocular surgery, and for the treatment of endogenous anterior uveitis.

[Read more: Rolling with the punches: Generics firms innovate, expand scope to stay competitive]

Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA.

Cipla’s product will be available for shipping soon.

Advertisement
Advertisement